It all began about a decade ago when a mysterious disease--later identified as the West Nile virus--was killing large goose populations at the South Dakota-based Schiltz Goose Farm. A group of researchers, led by Dr. David Bradley, executive director of the Center of Research Excellence for Avian Therapeutics for Infectious Diseases at the University of North Dakota, discovered antibodies in the yolks of goose eggs that they could purify and put back into other birds as a successful treatment. The Mayo Clinic called their find "game changing."
Soon a company called Avianax was formed to explore whether the treatment could be used beyond geese. They found promising links between the goose antibodies and treatments for other diseases, including rabies, dengue fever, avian flu, and some cancers. Their first focus was on the parvo virus and initial trials on their ParvoONE treatment resulted in a stunning 90 percent cure rate in as little as two days.
Avianax will be running more trials on ParvoONE through November, but if the U.S. Department of Agriculture gives the go-ahead, Avianax plans on selling the treatment next spring for $75 per dose. Avianax is also starting to work on a human application of the antibody treatment for other diseases.